MGX Metagenomi: Forward P/E Multiple

Graphic logo of Metagenomi, Inc. (MGX)

The lack of operating cash flow and capital expenditure on early-stage research are putting pressure on quotes, which confirms the forward P/E multiple of Metagenomi, Inc. (MGX). The value of 0.00 determines the current status of the parameter. The business fundamentals rely on metagenomics patents and royalties from pharma behemoths, the use of AI to discover genome editing systems, and future sales of therapies for rare pathologies.

Price to Future Earnings Ratio: Metagenomi (MGX) for 02/21/2024 - 11/17/2026

Metric breakdowns and analytics for Metagenomi, Inc. (MGX)

- stock quotes and analyst forecast:
Basic company analysis:Metagenomi, Inc MGX
Signature product of Metagenomi Therapeutics

The forward P/E reflects the ratio of current market value to projected earnings per share, measuring market expectations regarding the pace of asset monetization. By analyzing the valuation of Metagenomi, Inc. (MGX) via the forward P/E, an investor can discern the capitalization's sensitivity to the binary risks associated with a narrow DNA editing profile, where a strategic partnership with a pharma behemoth serves as the key stabilizer of the company's fundamental value.

Direct competitors

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience Corp (TWST)|Projected Price to Earnings 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS - Future Price to Earnings|Wave Life Sciences (WVE) - Projected Price to Earnings|MAZE: Forward P/E Multiple|Sionna Therapeutics, Inc. (SION) - Forward P/E Multiple|Future Price to Earnings Prime Medicine, Inc.|TSHA (Taysha) - Market Cap to Future Earnings Ratio|Projected Price to Earnings QURE (uniQure Pharma)|Market Cap to Projected Earnings meiragtx.com|Future Price to Earnings REGENXBIO RGNX|SLDB - Projected Price to Earnings|Ocugen, Inc. - Forward P/E Multiple|PACB (Pacific Biosciences of California) - Price to Future Earnings Ratio|BNTC: Forward P/E Multiple|DSGN - Market Cap to Projected Earnings|RCKT (Rocket Pharma) - Forward P/E Multiple|Future Price to Earnings FDMT|Future Price to Earnings Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Price to Future Earnings Ratio|editasmedicine.com - Projected Price to Earnings|Market Cap to Projected Earnings silence-therapeutics.com (SLN)|PRQR: Projected Price to Earnings|Projected Price to Earnings Ratio codexis.com|SGMO: Forward P/E Multiple|Projected Price to Earnings Ratio Nautilus Biotechnology Inc (NAUT)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple